Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china

OBJECTIVE: The aim of this study was to evaluate the cost-effectiveness of durvalumab compared with Best supportive care (BSC) after chemoradiotherapy in patients with stage III non-small cell lung cancer from healthcare system perspective in China. METHODS: A dynamic state transition model was adop...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Xiaotong, Chen, Jinyu, Zheng, Min, Jia, Hanxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231800/
https://www.ncbi.nlm.nih.gov/pubmed/35749385
http://dx.doi.org/10.1371/journal.pone.0270118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9231800/
https://www.ncbi.nlm.nih.gov/pubmed/35749385
http://dx.doi.org/10.1371/journal.pone.0270118

Ejemplares similares